Scarica l'app Stockscreener
15.53
8.32%
-1.41
Dopo l'orario di chiusura:
15.70
0.17
+1.09%
Precedente Chiudi:
$16.94
Aprire:
$16.83
Volume 24 ore:
2.99M
Relative Volume:
0.90
Capitalizzazione di mercato:
$971.08M
Reddito:
$16.10M
Utile/perdita netta:
$-198.97M
Rapporto P/E:
-4.4615
EPS:
-3.4809
Flusso di cassa netto:
$-183.99M
1 W Prestazione:
+8.83%
1M Prestazione:
-24.24%
6M Prestazione:
-5.79%
1 anno Prestazione:
+12.70%
Intervallo 1D:
$15.04
$17.29
Intervallo di 1 settimana:
$15.04
$19.22
Portata 52W:
$7.76
$71.50
Uniqure N V Stock (QURE) Company Profile
Nome
Uniqure N V
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
15.53 | 971.08M | 16.10M | -198.97M | -183.99M | -3.4809 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2026-03-09 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | Downgrade | Mizuho | Outperform → Neutral |
| 2026-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | Iniziato | Wolfe Research | Peer Perform |
| 2026-01-28 | Iniziato | Barclays | Equal Weight |
| 2025-11-04 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure N V Borsa (QURE) Ultime notizie
QURE INVESTOR ALERT: Contact Kirby McInerney LLP About Securities Class Action Lawsuit On Behalf of uniQure N.V. Investors - ACCESS Newswire
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - PR Newswire
uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz - GuruFocus
UniQure to rally around 92%? Here are 10 top analyst forecasts for Wednesday - MSN
uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline - ChartMill
Why (QURE) Price Action Is Critical for Tactical Trading - Stock Traders Daily
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
QURE Shareholder Alert: April 13, 2026 Lead Plaintiff Deadline in uniQure N.V. Securities Class ... - Bluefield Daily Telegraph
UniQure Faces AMT-130 Scrutiny As FDA Shifts And Lawsuits Weigh - Sahm
uniQure (QURE) Upgraded to Outperform by Mizuho, Price Target Ra - GuruFocus
uniQure upgraded at Mizuho on improved outlook for Huntington's asset AMT-130 - Seeking Alpha
QURE ALERT: FDA Reportedly Accuses uniQure of Pushing "Distorted" and "Manipulated" Data For "Failed" AMT-130 Drug Amid Pending Securities Class ActionHagens Berman - PR Newswire
A Unique Situation For UniQure (QURE) - Seeking Alpha
Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming DeadlinesQURE - PR Newswire
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard - GlobeNewswire
QURE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that uniQure N.V. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
HC Wainwright Has Negative Forecast for uniQure Q1 Earnings - MarketBeat
Atika Capital Management LLC Invests $5.25 Million in uniQure N.V. $QURE - MarketBeat
Lawsuit filed for Investors who lost money with shares of uniQure N.V. (NASDAQ: QURE) - openPR.com
uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V.QURE - GlobeNewswire
uniQure Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
uniQure N.V. (QURE) Investors: April 13, 2026, Deadline in Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP - NewMediaWire
QURE LAWSUIT ALERT: Levi & Korsinsky Notifies uniQure N.V. Investors of a Class Action Lawsuit and Upcoming Deadline - Morningstar
QURE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 – Company AnnouncementFT.com - Financial Times
Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
uniQure (QURE) Gains Momentum with Mizuho's Rating Upgrade and Price Target Raise | QURE Stock News - GuruFocus
uniQure N.V. Securities Fraud Class Action Result of FDA - GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages uniQure N.V. - GlobeNewswire
Stock Market Today: Dow Jones, S&P 500 Futures Plunge As Oil Prices Jump, Trump Dismisses 'Short Term' Spike—Hims & Hers, Ovintiv, Uniqure In Focus - Sahm
Why Is uniQure Stock Skyrocketing Monday? - Sahm
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines – QURE - ChartMill
FinancialContentINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines – QURE - FinancialContent
QURE stock’s relentless rally continues today — here's why HC Wainwright is bullish on uniQure - MSN
UniQure N.V. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm Before April 13, 2026 to Discuss Your RightsQURE - marketscreener.com
A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $31 to $70 - 富途牛牛
uniQure N.V. Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm Before April 13, 2026 to Discuss Your RightsQURE - Morningstar
uniQure's (QURE) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that uniQure N.V. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
uniQure Shares Surge 26% On US FDA Shakeup Even As Momentum Tumbles: Will New Leadership Greenlight Huntington's Therapy? - Benzinga
QURE: HC Wainwright & Co. Reiterates Buy Rating with $70 PT | QU - GuruFocus
uniQure (QURE) Shares Set for Growth Amid Regulatory Changes - GuruFocus
Jefferies Financial Group Inc. Reduces Holdings in uniQure N.V. $QURE - MarketBeat
QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure - Stocktwits
UNIQURE N.V. (QURE) DEADLINE ALERT Bernstein Liebhard LLP Reminds uniQure N.V. Investors of Upcoming Deadline - ACCESS Newswire
uniQure N.V. (NASDAQ:QURE) Given Consensus Rating of "Hold" by Analysts - MarketBeat
uniQure (QURE) awards stock options and RSUs to chief customer officer - Stock Titan
UniQure N.V. (QURE): RBC Capital Upgrades Rating to Outperform With Significant Upside Potential - 富途牛牛
uniQure Faces Investor Lawsuit Over Misleading Statements - Intellectia AI
Forecast brighter for Uniqure with Prasad’s departure? - bioworld.com
Uniqure N V Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):